Ivabradin Sandoz

Active Ingredient:: Ivabradine
Origin:: EU

Ivabradin Sandoz (Ivabradine)

Q: What conditions is Ivabradin Sandoz used for?

Ivabradin Sandoz is prescribed to manage chronic stable angina and heart failure with reduced ejection fraction. In both conditions, the drug lowers heart rate, which helps reduce myocardial oxygen demand and improves symptoms such as chest pain and dyspnea.

Q: How does ivabradine work to lower heart rate?

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. By inhibiting this current, the drug slows the spontaneous depolarisation of pacemaker cells, resulting in a controlled reduction of heart rate without affecting contractility or blood pressure.

Q: What is the usual dose of Ivabradin Sandoz?

The dosage of Ivabradin Sandoz is individualized by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and response to therapy. The prescriber determines the appropriate strength, frequency, and any necessary titration.

Q: Is Ivabradin Sandoz safe during pregnancy or breastfeeding?

Safety of ivabradine in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

Q: How do I order Ivabradin Sandoz from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Ivabradin Sandoz compare with beta‑blockers?

Both ivabradine and beta‑blockers lower heart rate, but ivabradine acts selectively on the If channel without beta‑adrenergic blockade, preserving contractility and blood‑pressure effects. It is often considered when patients cannot tolerate beta‑blockers or need additional heart‑rate control.

Q: What are the recommended storage conditions for Ivabradin Sandoz?

Ivabradin Sandoz tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children.

Q: How is Ivabradin Sandoz administered?

The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Q: What are the most serious risks associated with Ivabradin Sandoz?

Serious risks include severe bradycardia, atrial fibrillation, symptomatic hypotension, and atrioventricular block. Patients should be monitored for signs of these events, especially when initiating therapy or adjusting dose.

Q: Who should not use Ivabradin Sandoz?

Ivabradin Sandoz is contraindicated in patients with severe hypotension, sick sinus syndrome, second‑ or third‑degree atrioventricular block (unless a pacemaker is present), and in those with a resting heart rate below 50 bpm. It should also be avoided in individuals with known hypersensitivity to ivabradine.

Ivabradine, the active ingredient in Ivabradin Sandoz, is an If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH India supplies Ivabradin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide from its EU‑origin manufacturing network. Our distribution adheres to stringent quality standards and regulatory requirements.

Manufacturer / TM Owner

Sandoz Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradin Sandoz acts on the cardiac If current to control heart rate in specific cardiovascular conditions.

Chronic stable angina: improves exercise tolerance by lowering myocardial oxygen demand.
Heart failure with reduced ejection fraction: reduces heart rate, alleviating symptoms and decreasing hospitalization risk.
Patients intolerant to beta‑blockers: offers an alternative means of heart‑rate control without beta‑adrenergic blockade.

How It Works

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which slows depolarisation of pacemaker cells. By reducing the slope of phase 4 depolarisation, the drug lowers spontaneous heart‑rate generation without affecting myocardial contractility or intracardiac conduction, leading to a controlled reduction in heart rate.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

Visual disturbances (phosphenes): transient luminous phenomena.
Bradycardia: heart rate slower than intended.
Headache: mild to moderate intensity.
Dizziness or vertigo.
Fatigue or tiredness.
Blurred vision.

Serious or Rare Side Effects

Severe bradycardia requiring medical attention.
Atrial fibrillation or other arrhythmias.
Symptomatic hypotension.
Symptomatic atrioventricular block.
Syncope (fainting).
Allergic reactions such as rash or angioedema.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for adverse events.

Baseline heart rate assessment: ensure resting rate is ≥50 bpm before starting.
Severe hypotension: avoid use in patients with systolic BP <90 mmHg.
Hepatic impairment: dose adjustment may be required in moderate to severe liver disease.
Sick sinus syndrome or atrioventricular block: contraindicated unless a pacemaker is present.
Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Ivabradin Sandoz may interact with several concomitant medicines, influencing its plasma concentration or additive pharmacodynamic effects.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole): may markedly increase ivabradine levels.
Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may substantially reduce efficacy.
Other bradycardic agents (e.g., beta‑blockers, digoxin): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely)

Verapamil or diltiazem: moderate CYP3A4 inhibition can raise ivabradine concentrations.
CYP3A4‑modulating antidepressants (e.g., fluoxetine, sertraline): monitor heart rate and symptoms.
Antihypertensives: observe for additive blood‑pressure lowering effects.

Frequently Asked Questions

Ivabradin Sandoz is prescribed to manage chronic stable angina and heart failure with reduced ejection fraction. In both conditions, the drug lowers heart rate, which helps reduce myocardial oxygen demand and improves symptoms such as chest pain and dyspnea.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. By inhibiting this current, the drug slows the spontaneous depolarisation of pacemaker cells, resulting in a controlled reduction of heart rate without affecting contractility or blood pressure.

The dosage of Ivabradin Sandoz is individualized by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and response to therapy. The prescriber determines the appropriate strength, frequency, and any necessary titration.

Safety of ivabradine in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine acts selectively on the If channel without beta‑adrenergic blockade, preserving contractility and blood‑pressure effects. It is often considered when patients cannot tolerate beta‑blockers or need additional heart‑rate control.

Ivabradin Sandoz tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children.

The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe bradycardia, atrial fibrillation, symptomatic hypotension, and atrioventricular block. Patients should be monitored for signs of these events, especially when initiating therapy or adjusting dose.

Ivabradin Sandoz is contraindicated in patients with severe hypotension, sick sinus syndrome, second‑ or third‑degree atrioventricular block (unless a pacemaker is present), and in those with a resting heart rate below 50 bpm. It should also be avoided in individuals with known hypersensitivity to ivabradine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.